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Absolute quantifi cation of CSF Tau isoforms by a simple and cost-effective purifi cation and µLC-MS/HRMS
I presently work as post doctoral researcher in the Drug 
Metabolism Research Laboratory (LEMM, Laboratoire d’Etude 
du Métabolisme des Medicaments). LEMM belongs to the 
CEA (Commissariat à l’Energie Atomique, French Atomic 
Commission) and is located at Saclay in the south of Paris. 
The laboratory, headed by Dr. Christophe Junot, develops 
analytical and cellular tools to support drug development and 
biomarker discovery. One of the fi elds of excellence is the use 
of mass spectrometry (MS) to investigate biological systems. To 
this end, the laboratory develops and implements (i) targeted 
approaches for the elucidation of drug metabolism, intracellular 
pharmacokinetics, (ii) global approaches for metabolomics, and 
more recently, lipidomics and glycomics, and (iii) quantitative 
analyses of proteins using triple quadrupole and high resolution 
instruments, applied to, protein drugs, biological warfare (toxins, 
bacteria) and biomarkers of neurodegenerative diseases, area in 
which I conduct my researches. LEMM is equipped with various 
mass spectrometers for targeted or untargeted approaches 
(triple quadrupoles, Orbitrap, Maldi-TOF, Q-TOF, Q-Orbitrap). 
My research activity is supervised by Dr. François Becher with 
partnership with the Clinical Proteomics Platform of Montpellier 
University Hospital headed by Pr. Sylvain Lehmann in the frame 
of French Hospital Clinical Research Program (PHRC). We are 
focused on MS strategies development to monitor key biomarkers 
of Alzheimer disease (AD) in cerebrospinal fl uid (CSF) and 
provide alternative information to supplement immunoassay 
analyses. We are particularly interested in Tau protein involved in 
numerous neurological disorders or “tauopathies” including AD.
However, detection of Tau in CSF by MS is challenging 
due to protein heterogeneity (six splicing variants, many 
described truncated forms and extensive post-translational 
modifi cations) and very low concentration expected in CSF 
(100 to 1000 pg/ml). To overcome this challenge, we have 
developed an original extraction at the protein level based on 
Tau specifi c physico-chemical properties. Without antibodies 
requirement, this extraction step allows an effective depletion 
of major CSF proteins and Tau concentration prior digestion 
and peptides analysis by MS. To achieve sensitive detection 
required to quantify CSF Tau peptides, we have also developed 
a LC-HRMS platform based on Q-Orbitrap mass spectrometer. 
Thanks to scheduled Parallel Reaction Monitoring (PRM), 
we are fi nally able to target 26 Tau peptides whose 22 are 
successfully detected and quantifi ed in CSF extracts.
I have presented these fi ndings at an oral communication 
during the 61st ASMS conference in Minneapolis. These results 
have been also the subject of two oral communications by Dr. 
Christophe Hirtz at the 12th HUPO and 6th CTAD congresses.
We have performed absolute quantifi cation of all detected CSF 
Tau peptides using recombinant labeled Tau and compared our 
results obtained for t-Tau ELISA on 50 samples from a clinical 
cohort. Quantifi cation results allow peptides stoichiometry study 
and inferring major CSF Tau proteoforms. MS data appears more 
informative and with higher diagnosis utility than t-Tau ELISA 
to discriminate AD patients from other neurological diseases, 
especially in the context of shared high CSF tau concentration.
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Fig. Superimposed extracted ion chromatograms of 22 Tau peptides obtained from a digest of CSF extract analyzed by scheduled PRM. Red 
signals correspond to exons inserts specifi c peptides. Their absolute quantifi cation allows assessment of Tau isoforms in CSF extracts.
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